ClinicalTrials.gg
Status unknownNCT03263455k-neglectUpdated Aug 28, 2017

Kinesio-Taping in Stroke Patients With Visuospatial Neglect

An interventional study of Kinesio taping group and Sham Taping in Stroke and Motor Disorder, sponsored by Universita di Verona. Status unknown at 2 sites in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-08-28.

Sponsored by Universita di Verona · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 14 studies in Stroke by Universita di Verona — 2 open to participants now, 2 under way, none of them phase 3. Stroke · Universita di Verona.

Planned enrollment
7th of 10
50 · median 76
Started
2017
with 3 others
No phase
10 of 14
1 open now
Registered
3rd of 14
by date

Among the 14 studies in Stroke by Universita di Verona, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2017, is one of 10 with no phase, and was the 3rd registered.

Stroke

8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.

Browse Stroke studies →

Open to participants now

2 of the 14 studies in Stroke by Universita di Verona are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,415 Stroke studies recruiting now, 697 (49%) set no upper age limit and 280 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Stroke by Universita di Verona, or all of them as a file.
02

Study summary

Stroke is the second leading cause of death worldwide and the third most common cause of disability. The effects of stroke are variable and may include impairments in motor and sensory systems, emotion and neuropsychological deficits such as a disorder of spatial awareness known as unilateral spatial neglect (USN). Approaches to ameliorate USN could be categorized in interventions as involving either bottom-up or top-down processing. The specific mechanisms underlying these effects on a number of manifestations of the USN syndrome may include the restoration of defective representations of the side of space contralateral to the lesion (contralesional), and of the ability to orient spatial attention contralesionally, through complex patterns of activation of both the damaged right hemisphere, and the contralateral left hemisphere, with differences related to the specific stimulation delivered to the patient. In recent years, increasing cutaneous stimuli through neuromuscular kinesiotaping has been proposed to enhance somatosensory inputs (24) and such as method could have positive effects on USN. The aim of the present study was to assess the effect of KTM applied on the sternocleidomastoid muscle controlateral side of the lesions in improving USN deficits in individuals with stroke patient in sub-acute phase. The hypothesis is that the KTM application could improved cognitive tests for assessing USN, motor deficits and kinesthetic neck sensibility.

03

Conditions studied

  • Stroke
  • Motor Disorder

Keywords

  • neglect,
  • stroke,
  • rehabilitation,
  • range of motion
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients affected by stroke from cerebral ischemia or hemorrhage that occurred ⩽ 30 days before;
  • presence of visuospatial neglect (Star Cancellation Test' score \< 50)
  • able to actively rotate the head toward left side in closed eyes condition.

Exclusion criteria

Exclusion Criteria:

  • the presence of dementia ( correct score lower than 23,80)
  • severe deficit of comprehension
  • psychiatric disorders
  • hemianopsia patients (diagnosed with perimetry) patients or their family members did not consent to this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Kinesio Taping group

    The tape in the KT group was applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension).

    Other: Kinesio taping group

  • Sham comparator
    Sham Taping group

    Patients in the ST group, smaller "I-strips" of KinesioTape were used and they were applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the Kinesio Taping group

    Other: Sham Taping

Interventions

  • OtherKinesio taping group

    The tape in the KT group will be applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension). KinesioTape will be applied over the SCM dystonic muscle by means of 2 "I-strips": the first strip will be placed on the medial (sternal) head and the second will be applied on the lateral (clavicular) head of the SCM muscle. KinesioTape was applied from the mastoid bone to the clavicle (rostrocaudal direction) with the SCM placed in a position of maximum stretching.

  • OtherSham Taping

    Patients in the ST group, smaller "I-strips" of KinesioTape will be used and they will be applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the experimental group. Although the specific therapeutic elements of KinesioTaping (ie, longitudinal stretch, start and ending point tape application) will be removed

06

What researchers measure

Primary outcomes

  1. The Stars Cancellation Test change in number of stars deleted

    Time frame: Baseline time 0 and up to 4 weeks

Secondary outcomes

  1. Number of letter delete during the Letter Cancellation Test

    Time frame: Baseline time 0 and up to 4 weeks

  2. Number of Error assessed during the Cervical Joint Position Error Test

    Time frame: Baseline time 0 and up to 4 weeks

  3. Degree of Active Range of Motion (AROM) during left rotation

    Time frame: Baseline time 0 and up to 4 weeks

07

Study locations

2 sites
  • Azienta Ospedaliera, SSO Rehabilitation Unit, Verona
    Verona, Italy, Verona 37134, Italy
  • Azienta Ospedaliera, SSO Rehabilitation Unit, Verona
    Verona, 37134, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2017; primary completion for Nov 2017, 2 months later.

Of 3,108 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 2 months is below that.

Counting every sponsor, half of 3,252 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2017
First posted
Aug 28, 2017
StartEst.
Sep 1, 2017
Primary completionEst.
Nov 30, 2017
CompletionEst.
Aug 1, 2018
Last update
Aug 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03263455
Responsible party
Nicola Smania, MD, Clinical Professor (Full Professor, Universita di Verona) — Principal investigator
First posted
Aug 28, 2017
Start date
Sep 1, 2017 (estimated)
Primary completion
Nov 30, 2017 (estimated)
Completion
Aug 1, 2018 (estimated)
Last update
Aug 28, 2017

Study contacts

Valentina Varalta, PS
Contact
valentina.varalta@univr.it
00390458124950
Daniele Munari, PT
Contact
daniele.munari@univr.it
00390458124950
Nicola Smania, MD
principal investigator · Neuromotor and Cognitive Rehabilitation Center Department for Neurosciences, Biomedicine and Movement Sciences University of Verona, Verona, Italy P.zza L.A. Scuro, 10 37134 Verona, Italia
Alessandro Picelli, MD
study director · Neuromotor and Cognitive Rehabilitation Center Department for Neurosciences, Biomedicine and Movement Sciences University of Verona, Verona, Italy P.zza L.A. Scuro, 10 37134 Verona, Italia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion